Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must be willing and able to provide informed consent.~* The patient is a male between \>30 and \<80 years of age.~* PDE5i responsive or non-responsive. If on PDE5i patient will discontinue medication for 4 weeks before IIEF.~* Stable sexual relationship for over 3 months prior to enrollment.~* A minimum of 2 sexual attempts per month for at least one month prior to enrollment.~* Erectile dysfunction lasting for over 6 months and not more than 5 years.~* Baseline IIEF-EF score between 11 and 25. If taking PDE5i, stop medication for at least 4 weeks before baseline IIEF-EF.~* Testosterone level 300-1000 ng/dL.~* If diabetic, HgbA1C level ≤ 7.5% within 1 month prior to enrollment.~Exclusion Criteria:~* The patient is currently or has participated in another study within the past three months, that may interfere with the results or conclusions of this study.~* The patient is under judicial protection (prison or custody).~* The patient is an adult under guardianship.~* The patient refuses to sign the consent.~* History of radical prostatectomy or extensive pelvic surgery ever.~* Past radiation therapy of the pelvic region within 12 months prior to enrollment.~* Recovering from any cancer within 12 months prior to enrollment.~* Neurological disease such as Alzheimers or Parkinsons disease which affects erectile function at the discretion of the investigator.~* Psychiatric diagnosis or medications such as antidepressants which affects erectile function or any other medications at the discretion of the investigator.~* Anatomical malformation of the penis, including Peyronie's disease.~* Testosterone level \<300 or \>1000 ng/dL within 1 month prior to enrollment.~* HgbA1C level \> 7.5% within 1 month prior to enrollment.~* Androgen deprivation treatment in the last year.~* History of spinal cord injury.~* The patient is taking blood thinners (eg Coumadin, Plavix)

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 720 shockwave therapy (Type: ACTIVE_COMPARATOR): 5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
- 600 shockwave therapy (Type: ACTIVE_COMPARATOR): Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).